Ketamine Therapy Cost: IV Infusions, Spravato vs. Ketamine, and Insurance Coverage

In 2010, ketamine was a Schedule III veterinary anesthetic that showed up in depression research papers. By 2025, it’s a mainstream treatment option for treatment-resistant depression, and it works fast — often within hours rather than weeks.

It’s also expensive. Here’s what it costs, what insurance covers, and who it’s actually for.

What Ketamine Therapy Costs

Ketamine is administered in mental health settings in two ways: IV (intravenous) infusions at specialty clinics, or as Spravato (esketamine) nasal spray at certified healthcare facilities. The costs are very different.

IV Ketamine Infusions: How It Works

IV ketamine infusions are delivered at specialty ketamine clinics (not at standard psychiatric offices or hospitals). A typical infusion involves:

• 40–60 minute IV infusion of subanesthetic-dose ketamine
• Monitoring by a medical professional (typically an anesthesiologist or registered nurse)
• A recovery period of 30–60 minutes before leaving

The standard protocol for treatment-resistant depression: 6 infusions over 2–3 weeks. At $400–$800 per infusion, the initial course runs $2,400–$4,800.

Maintenance infusions (to sustain response): some patients need booster infusions every 4–8 weeks. Long-term, this adds $300–$600 per session, indefinitely.

Insurance coverage: Almost none for IV infusions. Insurance rarely covers IV ketamine because it’s not FDA-approved for psychiatric use (it’s off-label, though commonly practiced). Some patients have successfully appealed for reimbursement by documenting treatment-resistant depression, but this is the exception.

Spravato (Esketamine): The FDA-Approved Option

Spravato is an esketamine nasal spray developed by Janssen (Johnson & Johnson) and approved by the FDA in 2019 specifically for treatment-resistant depression and major depression with suicidal ideation.

Because it’s FDA-approved and delivered in certified healthcare facilities (not at home), insurance is more likely to cover Spravato than IV ketamine. Medicare and most large private insurers cover it after documented failure of at least two antidepressants.

Coverage requirements typically include:

• Diagnosis of treatment-resistant depression (2+ antidepressant failures at adequate dose/duration)
• Administration at a certified Spravato treatment center
• Patient monitoring at the facility for 2+ hours after each dose
• Prior authorization

With insurance coverage, patient costs typically run $0–$150 per session (copay/coinsurance). Without insurance, sessions run $800–$1,000 each.

The Janssen patient assistance program (SPRAVATO REMS program) provides financial assistance for patients who qualify. More information at janssen.com.

Ketamine vs. Spravato: Which to Choose?

The clinical decision depends on your situation, but cost is a major practical factor:

Choose Spravato if:

• You have insurance that covers it (most major insurers after prior auth)
• You meet the treatment-resistant depression criteria
• You’re willing to attend a certified facility twice per week initially

Consider IV ketamine if:

• You’re paying out of pocket and want faster results (IV produces effects faster and more reliably than nasal spray for some patients)
• Spravato is not available near you
• You’ve been recommended by a psychiatrist who specifically prefers IV for your presentation

Does Ketamine Therapy Work?

Yes, for the right patients. A 2023 meta-analysis in Molecular Psychiatry found that ketamine produced rapid antidepressant effects in 50–70% of treatment-resistant depression patients within 24 hours of the first infusion — results that often far exceed what standard antidepressants can achieve.

The limitation: response is often not permanent. Many patients require maintenance infusions. A treatment that costs $2,400–$4,800 upfront may become $300–$600/month for maintenance — adding up to $3,600–$7,200 per year for ongoing effect.